Impact of Incretin Therapy on Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes

 -Cell Dysfunction in Subjects With Impaired Glucose Tolerance and Early Type 2 Diabetes: Comparison of Surrogate Markers With First-Phase Insulin Secretion From an Intravenous Glucose Tolerance Test

(2008) A. Festa et al.   DIABETES

Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)

(2008) S. E. Kahn et al.   DIABETES CARE

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

(2008) T. Vilsbøll et al.   DIABETIC MEDICINE

Beta cell mass in diabetes: a realistic therapeutic target?

(2008) J. J. Meier   DIABETOLOGIA

Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice

(2008) Yusuke Moritoh et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Thiazolidinediones and the preservation of -cell function, cellular proliferation and apoptosis

(2007) Michael Decker et al.   DIABETES OBESITY & METABOLISM

Characterization of the Influence of Vildagliptin on Model-Assessed β-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia

(2007) Andrea Mari et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Protection of pancreatic beta-cells: Is it feasible?

(2007) Enzo Bonora   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES